NSE: ALIVUS
Alivus Life Sciences Ltd Share Price
Company information and financial fundamentals for Alivus Life Sciences Ltd, alongside its latest NSE share price.
About Alivus Life Sciences Ltd
Glenmark Life Sciences, a subsidiary of Nirma Limited, a diversified conglomerate with interest in consumer products, cement, chemicals and pharmaceuticals. It is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.
Classification: Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals · NSE symbol: ALIVUS
Company fundamentals
Figures are as reported by the company and compiled by screener.in (fetched 2026-11-09); they may lag the latest filing. Educational information, not investment advice.
Profit and loss, yearly (₹ crore)
| Mar 2019 | Mar 2020 | Mar 2021 | |
|---|---|---|---|
| Sales | 886 | 1,537 | 1,885 |
| Sales growth | — | +73% | +23% |
| Expenses | 639 | 1,065 | 1,294 |
| Operating Profit | 248 | 472 | 591 |
| OPM % | 28% | 31% | 31% |
| Other Income | 0 | 12 | 1 |
| Interest | 1 | 34 | 88 |
| Depreciation | 19 | 29 | 33 |
| Profit before tax | 228 | 421 | 471 |
| Tax % | 14% | 26% | 25% |
| Net Profit | 196 | 313 | 352 |
| EPS in Rs | 18.14 | 29.04 | 32.61 |
| Dividend Payout % | 0% | 0% | 0% |
Compounded growth
Balance sheet (₹ crore)
| Mar 2019 | Mar 2020 | Mar 2021 | |
|---|---|---|---|
| Equity Capital | — | — | — |
| Reserves | — | — | — |
| Borrowings | — | — | — |
| Other Liabilities | — | — | — |
| Total Liabilities | — | — | — |
| Fixed Assets | — | — | — |
| CWIP | — | — | — |
| Investments | — | — | — |
| Other Assets | — | — | — |
| Total Assets | — | — | — |
Cash flows (₹ crore)
| Mar 2019 | Mar 2020 | Mar 2021 | |
|---|---|---|---|
| Cash from Operating Activity | — | — | — |
| Cash from Investing Activity | — | — | — |
| Cash from Financing Activity | — | — | — |
| Net Cash Flow | — | — | — |
| Free Cash Flow | — | — | — |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | — | — | — |
Efficiency ratios
| Mar 2019 | Mar 2020 | Mar 2021 | |
|---|---|---|---|
| Debtor Days | — | — | — |
| Inventory Days | — | — | — |
| Days Payable | — | — | — |
| Cash Conversion Cycle | — | — | — |
| Working Capital Days | — | — | — |
| ROCE % | — | — | — |
Shareholding pattern (%)
| Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 82.85% | 75.00% | 75.00% | 74.99% | 74.94% | 74.91% | 74.91% | 74.87% | 74.87% | 74.85% |
| FIIs | 4.81% | 7.85% | 6.74% | 6.57% | 6.42% | 6.84% | 5.08% | 5.30% | 5.54% | 5.93% |
| DIIs | 1.57% | 4.16% | 4.86% | 5.19% | 5.62% | 5.47% | 7.13% | 7.27% | 7.18% | 7.03% |
| Public | 10.76% | 12.99% | 13.40% | 13.25% | 13.03% | 12.79% | 12.89% | 12.55% | 12.42% | 12.19% |
| No. of Shareholders | 1,49,396 | 1,43,960 | 1,46,840 | 1,41,977 | 1,38,500 | 1,35,643 | 1,32,748 | 1,27,969 | 1,25,559 | 1,22,777 |
Exchange disclosures
Recent bulk and block deals
| Date | Type | Client | Direction | Quantity | Avg price |
|---|---|---|---|---|---|
| 2026-11-06 | BLOCK | NIRMA LIMITED | Sold | 28,46,300 | 1370 |
| 2026-11-06 | BLOCK | PARAM CAPITAL | Bought | 7,29,729 | 1370 |
| 2026-11-06 | BLOCK | BANDHAN MUTUAL FUND | Bought | 6,00,000 | 1370 |
| 2026-11-06 | BLOCK | SETU SECURITIES PRIVATE LIMITED | Bought | 4,10,000 | 1370 |
| 2026-11-06 | BLOCK | SUBHKAM VENTURES I PVT LTD | Bought | 2,50,000 | 1370 |
Shown as filed with NSE. A filing shows that something happened, not why, and says nothing about what to do.
Compare ALIVUS with APOLLOHOSP →
Wondering what to do with Alivus Life Sciences Ltd?
This page shares company information and reported fundamentals. It does not tell you whether to buy, hold or sell. For a view that takes your own holding and goal into account, ask Samjho Bhai, our portfolio review tool.
Ask Samjho Bhai about ALIVUS →How this page works · New to company fundamentals? Start learning.
Key terms: Nifty 50 · Price-to-earnings ratio · Earnings per share · Dividend yield · Market capitalisation
Other Healthcare stocks in the NSE
Frequently asked questions
What is the NSE symbol for Alivus Life Sciences Ltd?
Alivus Life Sciences Ltd trades on the NSE under the symbol ALIVUS.
Where is Alivus Life Sciences Ltd listed?
Alivus Life Sciences Ltd is listed on the National Stock Exchange of India (NSE) under the symbol ALIVUS. It is not part of the NIFTY 50 or NIFTY 500 lists this site tracks.
Should I buy Alivus Life Sciences Ltd shares?
Market Dekho does not give buy, sell or hold recommendations and is not a SEBI-registered Research Analyst or Investment Adviser. To review a holding against your own goal and risk, you can use Samjho Bhai, or speak to a SEBI-registered adviser.
Prices are delayed and sourced from a public market-data provider; they may contain errors. This page is educational information, not investment advice.